DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts give DexCom an average recommendation of "Moderate Buy" from 24 firms (1 sell, 3 hold, 18 buy, 2 strong buy), with an average 12‑month price target of $86.50.
• DexCom recently beat quarterly estimates with EPS $0.68 versus $0.65 expected and revenue of $1.26 billion (up 13.1% YoY), reporting a net margin of 17.94% and ROE of 32.12%.
• The stock opened at $61.41, has a market cap of $23.7 billion and a P/E of 29.24, with a 12‑month range of $54.11–$89.98.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty-four research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating, eighteen have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $86.50.

Several equities research analysts have issued reports on DXCM shares. Piper Sandler reiterated an "overweight" rating on shares of DexCom in a research report on Thursday, February 5th. Citigroup lifted their target price on shares of DexCom from $77.00 to $84.00 and gave the company a "buy" rating in a research report on Wednesday, March 11th. Mizuho lifted their target price on shares of DexCom from $78.00 to $90.00 and gave the company an "outperform" rating in a research report on Friday, February 13th. Barclays reiterated an "underweight" rating and set a $72.00 target price (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Finally, Weiss Ratings upgraded shares of DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, March 4th.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $61.41 on Tuesday. The company has a 50 day moving average of $66.65 and a 200 day moving average of $66.55. The stock has a market cap of $23.70 billion, a P/E ratio of 29.24, a P/E/G ratio of 1.20 and a beta of 1.55. DexCom has a 12 month low of $54.11 and a 12 month high of $89.98. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company had revenue of $1.26 billion during the quarter, compared to analysts' expectations of $1.25 billion. During the same quarter in the previous year, the company earned $0.45 earnings per share. DexCom's revenue for the quarter was up 13.1% on a year-over-year basis. As a group, sell-side analysts forecast that DexCom will post 2.49 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of the business's stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the sale, the executive vice president directly owned 111,204 shares in the company, valued at approximately $7,010,300.16. The trade was a 1.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DexCom

A number of hedge funds have recently made changes to their positions in the business. HB Wealth Management LLC lifted its holdings in shares of DexCom by 50.7% in the 1st quarter. HB Wealth Management LLC now owns 7,474 shares of the medical device company's stock worth $469,000 after acquiring an additional 2,516 shares during the last quarter. World Investment Advisors lifted its holdings in shares of DexCom by 42.5% in the 1st quarter. World Investment Advisors now owns 92,737 shares of the medical device company's stock worth $5,824,000 after acquiring an additional 27,648 shares during the last quarter. New York State Teachers Retirement System lifted its holdings in shares of DexCom by 0.9% in the 1st quarter. New York State Teachers Retirement System now owns 305,198 shares of the medical device company's stock worth $19,166,000 after acquiring an additional 2,603 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of DexCom by 53.8% in the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 169,194 shares of the medical device company's stock worth $10,625,000 after acquiring an additional 59,150 shares during the last quarter. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. lifted its holdings in shares of DexCom by 2.8% in the 1st quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 28,781 shares of the medical device company's stock worth $1,807,000 after acquiring an additional 780 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.